Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

Mylan says Speculations of an Acquisition by Teva is a Rumour
Higher Gasoline Prices Lifts US Consumer Prices in March
Ahead of Apple’s Announcement of Earnings Report Analysts Forecast the Success R
Another Round of Layoff Announced by Schlumberger Cutting 11,000 jobs
Mattel and Quirky Unveil a Partnership to Create New Toys from Crowd Source
Washington Firms Hauling Greater Venture Capital Funds
The Foreclosure Activities in March Rise Sharply in the U.S
Slowdown in U.S. Crude Production Inches Brent crude Prices Higher
Japan Surpasses China as the Largest U.S. Bonds Holder
In a $2.5 Billion Deal, China’s Alibaba Injects Pharmacy Business into affiliate
Union Spends Huge Money for Low-Wage Campaign but Organizing Fast Food Workers i
Beijing Should Find the Right Mix of Policies to Perk up Growth